ReviewThe European journal of health economics : HEPAC : health economics in prevention and care2014
Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
Review in The European journal of health economics : HEPAC : health economics in prevention and care, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- A Study of the Comparability of the Pharmacodynamic, Toxicological, and Pharmacokinetic Properties of the Reference Drug Pulmozyme® and the Biosimilar Drug Tigerase®.Doklady. Biochemistry and biophysics · 2024Article
- Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.Global health research and policy · 2024Article
- Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.Frontiers in pharmacology · 2023Article
- Biosimilars in Oncology: Latest Trends and Regulatory Status.Pharmaceutics · 2022Review
- Real-World Impact of Switching From Insulin Glargine (LantusFrontiers in public health · 2022Article
- Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan.International journal of clinical practice · 2022Article
- Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.Frontiers in pharmacology · 2021Article
- Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany.International journal of environmental research and public health · 2020Article
- Potential Cost-Savings From the Use of the Biosimilars in Slovakia.Frontiers in public health · 2020Article
- Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price.International journal of clinical pharmacy · 2018Article
- The role of biosimilars in value-based oncology care.Cancer management and research · 2018Review
- Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.Frontiers in pharmacology · 2018Article
- Introduction of biosimilar insulins in Europe.Diabetic medicine : a journal of the British Diabetic Association · 2017Review
- Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis.PharmacoEconomics · 2017Review
- What drives the prescribing of growth hormone preparations in England? Prices versus patient preferences.BMJ open · 2017Observational
- Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.BMJ open · 2017Article
- Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.Journal of market access & health policy · 2017Article
- Key drivers for market penetration of biosimilars in Europe.Journal of market access & health policy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.